BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30040495)

  • 1. Stereotactic Ablative Body Radiotherapy for Primary Non-Small-Cell Lung Cancer: Achieving Local Control with a Lower Biologically Effective Dose.
    Zhu S; Lightsey JL; Hoppe BS; Okunieff P; Gopalan PK; Kaye FJ; Morris CG; Yeung AR
    Cancer Invest; 2018; 36(5):289-295. PubMed ID: 30040495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
    Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
    Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
    Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.
    Stephans KL; Djemil T; Reddy CA; Gajdos SM; Kolar M; Mason D; Murthy S; Rice TW; Mazzone P; Machuzak M; Mekhail T; Videtic GM
    J Thorac Oncol; 2009 Aug; 4(8):976-82. PubMed ID: 19633473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm.
    Latifi K; Oliver J; Baker R; Dilling TJ; Stevens CW; Kim J; Yue B; Demarco M; Zhang GG; Moros EG; Feygelman V
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1108-13. PubMed ID: 24529716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for central lung tumors, yes we can!
    Korzets Ceder Y; Fenig E; Popvtzer A; Peled N; Kramer MR; Saute M; Bragilovsky D; Schochat T; Allen AM
    Radiat Oncol; 2018 Apr; 13(1):77. PubMed ID: 29695273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
    Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
    Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer.
    Hiraoka M; Matsuo Y; Nagata Y
    Cancer Radiother; 2007; 11(1-2):32-5. PubMed ID: 17158081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
    J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation--CyberKnife.
    Brown WT; Wu X; Amendola B; Perman M; Han H; Fayad F; Garcia S; Lewin A; Abitbol A; de la Zerda A; Schwade JG
    Cancer J; 2007; 13(2):87-94. PubMed ID: 17476136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.